ALDH1A1 and breast carcinoma: According to a previous in silico research [68], the ellipticine reactive metabolites 13-hydroxyellipticine and 12-hydroxyellipticine are likely to be effective drugs for treating breast cancers with strong ALDH1A1 activity.